New hope for advanced cervical cancer: immune combo shows promise
NCT ID NCT04300647
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a new drug combination (tiragolumab plus atezolizumab) against atezolizumab alone in 172 people with advanced or returning cervical cancer that has a specific marker (PD-L1-positive). The goal was to see if the combination could shrink tumors better. Participants received treatment until their cancer worsened or side effects became too severe. This is a disease control study, not a cure, as ongoing management is needed.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CERVICAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Arizona Oncology Associates
Phoenix, Arizona, 85016, United States
-
Asan Medical Center
Seoul, 05505, South Korea
-
Augusta University
Augusta, Georgia, 30912, United States
-
Bialostockie Centrum Onkologi
Bialystok, 15-027, Poland
-
Centre Leon Berard
Lyon, 69008, France
-
Centre Régional de Lutte Contre Le Cancer Val D'aurelle Paul Lamarque
Montpellier, 34298, France
-
Centro Oncológico de Panamá
Panama City, 0801, Panama
-
Chang Gung Medical Foundation, Linkou Branch
Taoyuan City, 333, Taiwan
-
Chelyabisnk regional clinical center for oncology and nuclear medicine
Chelyabinsk, Sverdlovsk Oblast, 454087, Russia
-
Christus Muguerza Clinica Vidriera
Monterrey, Nuevo León, 64570, Mexico
-
Clinica CIMCA
San José, 10103, Costa Rica
-
Clinica Ricardo Palma
San Isidro, Lima 27, Peru
-
Clinica de Pesquisa e Centro de Estudos em Oncologia Ginecologica e Mamaria Ltda
São Paulo, São Paulo, 01317-000, Brazil
-
Complejo Hospitalario Universitario A Coruña (CHUAC)
A Coruña, 15006, Spain
-
Gangnam Severance Hospital
Seoul, 06273, South Korea
-
Gustave Roussy
Villejuif, 94800, France
-
Hospital Araujo Jorge
Goiânia, Goiás, 74605-070, Brazil
-
Hospital Nossa Senhora da Conceicao
Porto Alegre, Rio Grande do Sul, 91350-200, Brazil
-
Hospital Sao Lucas - PUCRS
Porto Alegre, Rio Grande do Sul, 90610-000, Brazil
-
Hospital Sao Rafael - HSR
Salvador, Estado de Bahia, 41253-190, Brazil
-
Hospital Universitario 12 de Octubre
Madrid, 28041, Spain
-
Hospital Universitario La Paz
Madrid, 28046, Spain
-
Hospital de Caridade de Ijui
Ijuí, Rio Grande do Sul, 98700-000, Brazil
-
ICIMED Instituto de Investigación en Ciencias Médicas
San José, 10108, Costa Rica
-
ICO - Site René Gauducheau
Saint-Herblain, 44805, France
-
Institut Paoli Calmettes
Marseille, 13009, France
-
Istituto Europeo Di Oncologia
Milan, Lombardy, 20141, Italy
-
Istituto Tumori Napoli
Naples, Campania, 80131, Italy
-
Jewish General Hospital
Montreal, Quebec, H3T 1E2, Canada
-
Kaiser Permanente - Irvine
Irvine, California, 92616, United States
-
Keimyung University Dongsan Hospital
Daegu, 41931, South Korea
-
Korea Cancer Center Hospital of Korea Institute of Radiological and Medical Sciences
Seoul, 01812, South Korea
-
London Regional Cancer Centre
London, Ontario, N6A 4L6, Canada
-
MEDSI Clinical Hospital on Pyatnitsky Highway
Moscow, Moscow Oblast, 143422, Russia
-
Mackay Memorial Hospital
Taipei, Taiwan
-
Maharaj Nakorn Chiang Mai Hospital
Muang, 50200, Thailand
-
Mater Misericordiae Limited
South Brisbane, Queensland, 4101, Australia
-
McGill University Health Centre - Glen Site
Montreal, Quebec, H4A 3J1, Canada
-
Narodowy Inst.Onkol.im.Sklodowskiej-Curie Panstw.Inst.Bad Gliwice
Gliwice, 44-101, Poland
-
Narodowy Instytut Onkologii im. M.Sklodowskiej-Curie
Warsaw, 02-781, Poland
-
National Taiwan University Hospital
Taipei, 110, Taiwan
-
Oncology Associates of Oregon, P.C
Eugene, Oregon, 97401, United States
-
Policlinico Universitario Agostino Gemelli
Rome, Lazio, 00168, Italy
-
Princess Margaret Cancer Center
Toronto, Ontario, M5G 1Z5, Canada
-
Republican Clinical Oncology Dispensary of Ministry of Healthcare of Tatarstan Republic
Kazan', Tatarstan Republic, 420029, Russia
-
Royal Victoria Regional Health Centre
Barrie, Ontario, L4M 6M2, Canada
-
Samsung Medical Center
Seoul, 06351, South Korea
-
Sarah Cannon Research Institute
London, W1G 6AD, United Kingdom
-
Seoul National University Hospital
Seoul, 03080, South Korea
-
Severance Hospital, Yonsei University Health System
Seoul, 03722, South Korea
-
Szpital Morski im.PCK
Gdynia, 81-519, Poland
-
Taichung Veterans General Hospital
Taichung, 40705, Taiwan
-
Taipei Veterans General Hospital
Taipei, 11217, Taiwan
-
The Panama Clinic
Panama City, 0832, Panama
-
Tomsk scientific research institute of oncology SO RAMN, PAD
Tomsk, 634050, Russia
-
University College London Hospital
London, NW1 - 2PG, United Kingdom
-
Volgograd Regional Clinical Oncology Dispensary
Volgograd, 400138, Russia
-
Wielkopolskie Centrum Onkologii im. M. Sklodowskiej-Curie
Poznan, 61-866, Poland
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new drug combo revive Immunotherapy's power against resistant tumors?
- Can an antiviral make radiation more effective against cervical cancer?
- A One-Two punch against cervical cancer: testing plus vaccination in HIV-Positive women
- Can a Two-Antibody combo outsmart advanced cancer?
- Can robotic surgery match open surgery in beating cervical cancer?
- Blood test clues could sharpen cervical cancer treatment